Gossamer Bio grants director option on 10,000 shares
The option's full vesting is conditional on Sandra Milligan continuing to serve on Gossamer Bio's board through the grant's first anniversary.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Gossamer Bio, Inc. director Sandra Milligan was granted a stock option covering 10,000 shares of common stock on September 23, 2026, with an exercise price of $10.99 per share. The reported post-grant position in this option was 10,000 underlying shares, and the option expires September 22, 2036. All shares subject to the option become fully vested and exercisable on the first anniversary of the grant, subject to Milligan's continued board service through that date. No Rule 10b5-1 plan is reported.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1 | 10,000 | $0.00 | $0.00 |
Footnotes (1)
- F1. The entire number of shares subject to this option becomes fully vested and exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
Key Figures
Key Terms
Stock Option (Right to Buy) financial
exercise price financial
fully vested and exercisable financial
continued service financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Was Sandra Milligan's GOSS option grant made under a Rule 10b5-1 plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.